AstraZenecaRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AstraZeneca (AZN) reported revenue of $15.38B in Q2 2026, with Total Oncology its largest revenue segment at 26%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
AstraZenecaUK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
AstraZeneca (AZN) is a Drug Manufacturers - General company. UK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo. It was founded in 1999, is headquartered in Cambridge, UK and employs about 89,900 people.
As of 2023-Q2, AstraZeneca's revenue breaks down across Total Oncology (26%), Farxiga (9%), Tagrisso (9%), BioPharmaceuticals: total Respiratory & Immunology (9%). See the revenue-by-segment chart for the full mix.
Track AstraZeneca's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 23, 2026.
Sterling groups AstraZeneca in the GLP-1 sector, alongside Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), Merck & Co. (MRK) and AbbVie (ABBV). Sterling also tracks it in the Vaccines sector.
If you are researching AstraZeneca, also look at Pfizer (PFE), Amgen (AMGN) and Roche (RHHBY). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.